RecruitingPhase 2Phase 3NCT05613608

Alcohol Use Disorder and Cannabidiol

Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies


Sponsor

University of Colorado, Denver

Enrollment

180 participants

Start Date

Apr 30, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.


Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cannabidiol and a drug called Placebo for people with alcohol use disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCannabidiol

The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.

DRUGPlacebo

Placebo arm.


Locations(1)

University of Colorado Anschutz

Aurora, Colorado, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05613608


Related Trials